- Home
- INSM
INSM
Insmed Incorporated
as 02-21-2025 4:00pm EST
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 14.3B | IPO Year: | 2000 |
| Target Price: | $92.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.92 - $84.87 | Next Earning Date: | 02-20-2025 |
| Revenue: | $363,707,000 | Revenue Growth: | 19.17% |
| Revenue Growth (this year): | 20.03% | Revenue Growth (next year): | 41.61% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bonstein Sara | INSM | Chief Financial Officer | Feb 11 '25 | Sell | $80.00 | 18,321 | $1,465,680.00 | 137,185 | |
| Adsett Roger | INSM | Chief Operating Officer | Feb 10 '25 | Sell | $78.24 | 42,975 | $3,378,066.75 | 172,223 | |
| Lewis William | INSM | Chair and CEO | Feb 5 '25 | Sell | $80.90 | 79,350 | $6,419,415.00 | 453,894 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 5 '25 | Sell | $80.25 | 33,115 | $2,678,924.90 | 138,053 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Feb 5 '25 | Sell | $80.90 | 23,500 | $1,901,150.00 | 120,878 | |
| Bonstein Sara | INSM | Chief Financial Officer | Feb 5 '25 | Sell | $80.90 | 28,390 | $2,296,751.00 | 137,185 | |
| Adsett Roger | INSM | Chief Operating Officer | Feb 5 '25 | Sell | $80.24 | 45,705 | $3,697,401.50 | 172,223 | |
| Wise John Drayton | INSM | Chief Commercial Officer | Feb 5 '25 | Sell | $79.91 | 7,920 | $640,708.10 | 133,015 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Feb 5 '25 | Sell | $80.90 | 20,650 | $1,670,585.00 | 96,610 | |
| Lewis William | INSM | Chair and CEO | Feb 3 '25 | Sell | $76.96 | 25,580 | $1,993,731.16 | 453,894 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
UBS Adjusts Insmed Price Target to $105 From $84, Maintains Buy Rating
MT Newswires
a day ago
Truist Securities Adjusts Insmed Price Target to $108 From $105, Maintains Buy Rating
Zacks
a day ago
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
Simply Wall St.
a day ago
Insmed Full Year 2024 Earnings: EPS Misses Expectations
GuruFocus.com
2 days ago
Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
MT Newswires
2 days ago
Insmed Insider Sold Shares Worth $1,471,394, According to a Recent SEC Filing
MT Newswires
2 days ago
Insmed Insider Sold Shares Worth $2,072,721, According to a Recent SEC Filing
Zacks
2 days ago
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.